News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Transgenomic, Inc. (TBIO) Announces Global Availability of CRC RAScan™ Mutation Detection Test for Use in Patients With Metastatic Colorectal Cancer to Help Identify Appropriate Treatment



5/16/2013 11:30:38 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB: TBIO) today announced the global, commercial availability of CRC RAScan™, a new mutation detection test to screen patients with metastatic colorectal cancer (mCRC) for RAS mutations (KRAS and NRAS). These RAS mutations, identified using the CRC RAScan™ kits which use Surveyor®-Wave® technology, provide physicians with important information regarding tumor mutation status to help with clinical treatment decisions for their mCRC patients. Transgenomic’s CLIA-certified laboratory in the United States (U.S.) is available immediately to receive patient samples for testing. In Europe, CE-IVD registered test kits are available for purchase. Research-only test kits will soon be available for purchase in the U.S.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES